

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
 (Not for submission under 37 CFR 1.99)

Application Number	10589840
Filing Date	2007-05-17
First Named Inventor	Maureen Caliguri
Art Unit	1628
Examiner Name	A. Pagonakis
Attorney Docket Number	GPC-298.1P US

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS							Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T5

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10589840
Filing Date	2007-05-17
First Named Inventor	Maureen Caligiuri
Art Unit	1628
Examiner Name	A. Pagonakis
Attorney Docket Number	GPC-298.1P US

/A.P./	1	Calabresi et al., Section IX Chemotherapy of Neoplastic Diseases - Introduction, Goodman & Gilman's The Pharmacological Basis of Therapeutics 10th ed., (J. Hardman, L. Limbird, and A. Gilman eds.), (McGraw-Hill, New York, 2001) (pp. 1381, 1383-1385 and 1388 provided)	<input type="checkbox"/>
/A.P./	2	Engblom et al., "Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines", British Journal of Cancer, 79(2): 286-292 (1999)	<input type="checkbox"/>
/A.P./	3	Engblom et al., "Carboplatin-Paclitaxel-and Carboplatin-Docetaxel-Induced Cytotoxic Effect in Epithelial Ovarian Carcinoma in Vitro", Cancer, 86: 2066-2073 (1999)	<input type="checkbox"/>
/A.P./	4	Fokkema et al., "JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin", Biochemical Pharmacology, 63: 1989-1996 (2002)	<input type="checkbox"/>
/A.P./	5	Gura, T., "Systems for Identifying New Drugs Are Often Faulty", Science, 278(5340): 1041-1042 (1997)	<input type="checkbox"/>
/A.P./	6	Kelland, L.R., "An update on satraplatin: the first orally available platinum anticancer drug", Exp. Opin. Invest. Drugs, 9 (6): 1373-1382 (2000)	<input type="checkbox"/>
/A.P./	7	Moreno et al., "Phase II study of docetaxel and cisplatin in first line treatment of disseminated small cell lung cancer (SCLC): Preliminary results", European Journal of Cancer, 35: S262 (1999)	<input type="checkbox"/>
/A.P./	8	Petrylak, D.P., "Docetaxel for the Treatment of Hormone-Refractory Prostate Cancer", Reviews in Urology, 5(Suppl. 2): S14-S21 (2003)	<input type="checkbox"/>
/A.P./	9	Van Putten et al., "Docetaxel and carboplatin combination as second-line treatment in metastatic non-small-cell lung cancer (NSCLC)", European Journal of Cancer, 37: S51 (2001)	<input type="checkbox"/>
/A.P./	10	Vogelstein et al., Chapter 1, In The Genetic Basis of Human Cancer 2nd ed., (B. Vogelstein and K. Kinzler eds.), (McGraw-Hill, 2002) p. 3.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10589840
Filing Date	2007-05-17
First Named Inventor	Maureen Caligiuri
Art Unit	1628
Examiner Name	A. Pagonakis
Attorney Docket Number	GPC-298.1P US

EXAMINER SIGNATURE

Examiner Signature	/Anna Pagonakis/	Date Considered	06/03/2010
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.